Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL

Dr. Neelapu shares results from the ZUMA-1 trial, in which treatment with anti-CD19 CAR T-cell therapy led to complete remissions in patients with relapsed diffuse large B-cell lymphoma.

SHARE